Sitagliptin with Dapagliflozin Tablets in 4 combination
Sitagliptin with Dapagliflozin Tablets are a fixed-dose oral antidiabetic combination formulated for patients with Type 2 Diabetes Mellitus (T2DM) requiring better glycemic control. This dual therapy provides complementary mechanisms of action to lower blood glucose effectively while reducing the risk of hypoglycemia compared to some other agents.
Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by promoting glucose excretion through the urine and offers additional benefits such as weight reduction and blood pressure improvement.
Combined in a single tablet, they simplify treatment regimens and improve patient compliance.
- Improves glycemic control in adults with Type 2 Diabetes when diet, exercise, or monotherapy is insufficient.
- May help reduce HbA1c levels effectively with once-daily dosing.
- Supports weight loss and may lower cardiovascular risk fact.
- Convenient fixed-dose combination reduces pill burden.
- Low risk of hypoglycemia when used alone or with metformin.